Meeting Archive:
Pulmonary Hypertension as a Complication of Scleroderma: A Guide for Patients and Caregivers

 
 

Meeting Description:

Dr. Roham Zamanian will discuss pulmonary complications of scleroderma. As a leading team member of the Stanford Pulmonary Hypertension (PH) Program, Dr. Zamanian can provide insights on the comprehensive diagnostic and therapeutic services to patients with all forms of pulmonary hypertension. Fifteen years ago, pulmonary hypertension was considered to be a uniformly progressive and fatal disease. While exciting new treatments have been developed since then, patients with pulmonary hypertension face a truly life-threatening illness. In the seventh in our series, Dr. Zamanian will shed light on research being done to develop new treatments and prolong the life of patients. 

Please contact us at:

Via email at: srfcure@sclerodermaRESEARCH.org

or call 1-800-441-CURE (2873)

Join the SRF community on:

Facebook

Twitter

YouTube

 

Details
Date: Tue, Oct 30, 2012
Time: 11:00 AM PDT
Duration: 1 hour
Host(s): Scleroderma Research Foundation
 Presenter Information
Roham Zamanian, MD, FCCP
Speaker Photo

Dr. Zamanian is the director of the adult pulmonary hypertension clinical service at Stanford Hospital and Clinics. He is also an assistant professor of medicine at the Stanford School of Medicine. Dr. Zamanian’s career has focused on translational and clinical research relating to pulmonary vascular diseases with a specific focus on pulmonary arterial hypertension. As a faculty member of the Vera Moulton Wall Center for Pulmonary Vascular Disease, he is dedicated to growing the translational capacity of the program. As such, he has developed the Stanford Pulmonary Hypertension Biobank as well as helped with improvement and implementation of the Wall Center Pulmonary Hypertension Database.

After migrating to the United States from Iran in 1984 (read about his adventurous journey here), Dr. Zamanian received his medical degree from University of California, Irvine College of Medicine in 1999.